Acelyrin Inc (NAS:SLRN)
$ 4.3 -0.17 (-3.8%) Market Cap: 431.40 Mil Enterprise Value: -107.36 Mil PE Ratio: 0 PB Ratio: 0.85 GF Score: 22/100

Q3 2023 ACELYRIN Inc Earnings Call Transcript

Nov 07, 2023 / 09:30PM GMT
Release Date Price: $9.2 (-1.81%)
Operator

Good day and thank you for standing by. Welcome to the ACELYRIN Q3 2023 Earnings Conference call. (Operator Instructions). Please be advised that today's conference is being recorded. I would now like to hand the conference over to Tyler Marciniak, Vice President of Investor Relations, Communications and Corporate Operations. Please go ahead.

Tyler Marciniak
ACELYRIN, Inc. - Vice President of Investor Relations, Communications and Corporate Operations

Thank you, Operator. Good afternoon, everyone, and thank you for joining us. Before we begin, I'd like to remind the audience that this conference call will contain forward-looking statements, such as those related to progress of our clinical trials and anticipated data readouts, our future financial and operating results and investments, and our ability to commercialize our product candidates. These forward-looking statements involve risks and uncertainties that could cause our actual results and events to differ materially.

We urge you to review the Risk Factors section of our Form 10-Q for the quarter

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot